Comparison study of the effect of erlotinib as a tyrosine kinase inhibitor on electrolyte levels in type2 diabetic and diabetic nephropathy

• Published in: Ibn Al-Haitham Journal for Pure and Applied Sciences Vol. 31; no. 3; pp. 63 - 69
• Main Authors: al-Khudayri, Zaynab Mahdi Abd, Ali, Bushra H.
• Format: Journal Article
• Language: English
• Published: Baghdad, Iraq University of Baghdad, College of Education for Pure Science / Ibn al-Haitham 19-11-2018; University of Baghdad
• Subjects: Diabetes mellitus type 2, diabetic nephropathy ,electrolyte (MgâºÂ²,CaâºÂ²,Naâº) ,erlotinib inhibitor
• DOI: 10.30526/31.3.2011
• EISSN: 2521-3407
• ISSN: 1609-4042

Diabetes mellitus can be defined as a metabolic disorder disease. Complication of
diabetes are due to diabetic nephropathy. This study was done in vitro to study the effect of
different concentrations of erlotinib inhibitor (tyrosine kinase inhibitor) on electrolyte levels
(Mg⁺², Ca⁺², Na⁺) in sera of Iraqi patients with newly diagnosis type2 diabetes and diabetic
nephropathy in addition to find the best percentage inhibition for utilizing different
concentrations from erlotinib (6.97x10⁻⁷, 9.30x10⁻⁷ ,1.16x10⁻⁶,1.39x10⁻⁶ ,1.62x10⁻⁵) molar
on electrolyte levels. This study was conducted in The National Diabetes Center, Al-
Mustansiriya University - Baghdad and included 150 patients divided into50 patients type 2
diabetic as group (G2), 50patients diabetic nephropathy as group(G3) and also 50 healthy as
control group(G1). The period time for aggregation the blood sampling was from July to
October 2017. All patients were within (18 to 60) year's age. Erlotinib (Tyrosine kinase
inhibitor) affected on serum Mg ⁺²levels in human as a mild effect and a slight effect on
serum Na⁺ and Ca⁺².The best inhibition of erlotinib in concentration (1.62x10⁻5) M for both
serum Na⁺ and Ca⁺² in newly diagnosis diabetes type 2 and diabetic nephropathy. Serum Mg
⁺²levels showed best inhibition in concentration (9.30x10⁻7) M.